Skip to main content
. 2014 Dec 31;6(7):4829–4844. doi: 10.18632/oncotarget.3104

Figure 2. Effect of AH6809/GW627368X on HB-EGF-, IGF-1-, and IGF-2-stimulated growth stimulation in pancreatic cancer cell lines.

Figure 2

A, Cells were stimulated with HB-EGF (50 ng/mL), IGF-1 (20 ng/mL), or IGF-2 (50 ng/mL) for 48 h in the absence or presence of AH6809/GW627368X (5 μM each) pretreatment for 3 h and cell growth was measured using the MTT assay. The A550 values for untreated cells were assigned as 100% and the relative percentages for the treated cells are shown. Columns, mean percentages (n = 6); bars, SD. B, BxPC-3 cells were stimulated with HB-EGF (50 ng/mL), IGF-1 (20 ng/mL) and IGF-2 (50 ng/mL) for 20 min in the absence or presence of AH6809/GW627368X (5 μM each) pretreatment for 3 h. The levels of phosphorylated MEK, total MEK, phosphorylated ERK, and total ERK were determined by immunoblotting. The relative levels of phospho-MEK and -ERK were calculated using ImageJ software.